-
Cell therapy for multiple myeloma: "what is now" and "what is next"
Time of Update: 2023-02-03
Major clinical studies of BCMA-targeted CAR T cell therapy in RRMM"What is next", how to further improve the therapeutic effect of cell therapyDespite the impressive clinical results achieved by cell therapy, no changes have been seen in the survival curve, and relapses occur frequently.
-
This combination regimen may improve outcomes for patients with relapsed/refractory mantle cell lymphoma in China
Time of Update: 2023-02-03
A phase II clinical study evaluating the efficacy and cytotoxicity of ibrutinib monotherapy as a salvage treatment for patients with MCL showed that the overall response rate (ORR) was 68%, the complete response rate (CR) was 21%, and the follow-up for 27 months showed long-lasting efficacy and good safety.
-
"Wan" is in the spotlight, "moving" road follows, domestic melphalon helps China's transplant field to flourish - Wanjia ® melphalon hydrochloride hydrochloride cloud summit forum for injection was successfully held!
Time of Update: 2023-02-03
Wanjia ® (melphalan hydrochloride for injection) was approved on August 23, 2022 by the original drug Alkeran® (50mg lyophilized powder needle propylene glycol solubilization) as the standard copy, an
-
Lymphoma Academy Professor Xu Wei: Interpretation of the 2022 edition of the Chinese guidelines for the diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
Time of Update: 2023-02-03
01 Treatment regimen recommendation for patients with DEL(17p)/TP53 gene mutation CLL without mutation:(1) For patients in good physical condition (including acceptable physical activity, creatinine clearance ≥70ml/min and CIRS score ≤6 points), priority is given: ibrutinib, zebratinib, fludarabine + cyclophosphamide + rituximab (for patients with IGHV mutations and age Other recommendations: orelabrutinib, venetoclax + rituximab/obinutuzumab, fludarabine + rituximab, fludarabine + cyclophosphamide.
-
HEMA Perspective Professor Ou Jinping: Life is endless, exploration is endless, and the diagnosis and treatment of gastrointestinal lymphoma is continuously optimized
Time of Update: 2023-02-03
Professor Ou JinpingOur center has cooperated with a number of well-known domestic lymphoma diagnosis and treatment centers to carry out PGIL-related research, among which, the retrospective study for PGIL patients not only discusses the factors affecting the survival of patients and the optimization of treatment plans, but also discusses the relationship between complications such as gastrointestinal obstruction, bleeding, and perforation and the prognosis of patients [1-2].
-
Professor Fu Chengcheng: Seliniso double-effect attack, anti-tumor and potential anti-COVID-19 effect!
Time of Update: 2023-02-03
Celiniso (trade name: Xivio ®) can effectively inhibit virus proliferation and pro-inflammatory cytokine release when treating the new coronavirus, while activating the release of anti-inflammatory cytokines, and has shown a certain efficacy in some patients with COVID-19 infection.
-
Ji Chunyan and Professor Wang Xin | Season 2: How to grasp the timing of 1L DLBCL treatment? Verptozumab focuses on clinical and value needs, steadily improving the "happiness" of treatment-naïve patients
Time of Update: 2023-02-03
FIGURE 8 THE POLARIX STUDY ESTIMATES THE NUMBER OF PATIENTS RECEIVING SECOND-LINE THERAPY FROM 2023 TO 2033The above research data shows that Pola-R-CHP regimen brings all-round benefits to treatment-naïve DLBCL patients, especially in the early stage of treatment, reducing the treatment burden of patients, helping to improve patients' "happiness", and bringing new choices and new hopes to the elderly and high-risk patient groups.
-
Ruichuang Biologics was approved for IND for the new indication of universal DNT cell therapy
Time of Update: 2023-02-03
January 8, 2023 / eMedClub News / -- January 6, 2023, Guangdong Ruishun Biotech Co. , Ltd. (hereinafter referred to as "Wyze Biotech CO. , Ltd. "), a biopharmaceutical company focusing on the R&D and
-
Final analysis of the phase III non-inferiority COLUMBA study: subcutaneous daratumab is non-inferior to intravenous injection
Time of Update: 2023-02-03
The primary analysis of the Phase III COLUMBA study demonstrated that DARA SC was non-inferior to DARA IV in terms of the common primary endpoint of efficacy (overall response rate [ORR]) and pharmacokinetics (maximum trough concentration [Ctrough], measured before dosing on day 1 of cycle 3).
-
Annual Inventory 2022 Multiple Myeloma Progress Summary (Part I) – Voice of Experts
Time of Update: 2023-02-03
Multiple myeloma (MM) is a malignant plasma cell disease, accounting for about 10% of hematologic malignancies, second only to non-Hodgkin lymphoma, and more likely to occur in middle-aged and elderly
-
Interim PET results identify aggressive NHL patients who would benefit from intensive therapy
Time of Update: 2023-02-03
The researchers who performed post-hoc analysis of the PETAL trial first used the PET data of the PETAL test to investigate whether the average FDG uptake value of lymphoma lesions predicted the patient's time to progression (TTP); Second, it investigated whether comprehensive iPET analysis could identify subgroups of patients who would benefit from intensive therapy.
-
International perspective| progress in the treatment of high-risk myelodysplastic syndrome
Time of Update: 2023-02-03
Compared with single-agent HMA, the ORR and CR rates in the combination group were 57% and 20%, respectively, with no significant improvement, but there were good results in duration of response (DOR), objective response and CR duration were 17 and 19 months, respectively, and patients with high-risk MDS, including TP53 mutations, also achieved good efficacy, with a DOR of 21.
-
Annual inventory of new drugs and new protocols approved by the FDA for hematologic malignancies in 2022
Time of Update: 2023-02-03
The approval is based on the AG120-C-009 study, details of which can be stamped: FDA Update | Approval of ivosnib in combination with azacitidine for the treatment of newly diagnosed patients with acute myeloid leukemiaThe recommended dose of ivoranib is 500 mg orally once daily, with or without food, until disease progression or intolerable toxicity.
-
2022 ASH Expert Interview | Professor Jorge Castillo: Exploration and prospect of targeted therapy for Waldenstrom macroglobulinemia
Time of Update: 2023-02-03
Table 2The results confirmed that the combination of the two drugs was very effective, however, the incidence of ventricular arrhythmias was higher than expected, which prompted the discontinuation of the study treatment, based on complications, which cannot be recommended for clinical use at this time, and I think future trials can also choose different drugs or low-toxicity drug combination therapy to develop treatment options.
-
2023CASH| Talk about the precise diagnosis and innovative treatment of MDS/MPN
Time of Update: 2023-02-02
With the gradual seriousness of China's aging society, the incidence of myelodysplastic syndrome (MDS) and myeloproliferative tumor (MPN), the most common myeloid neoplastic diseases in elderly patien
-
Annual Inventory 2022 Multiple Myeloma Progression Summary (Part II) - Research Progress
Time of Update: 2023-02-02
Multiple myeloma (MM) is a malignant plasma cell disease, accounting for about 10% of hematologic malignancies, second only to non-Hodgkin lymphoma, and more likely to occur in middle-aged and elderly
-
An important treatment option for patients with 1q21+ relapsed/refractory multiple myeloma – isatuximab-based combination therapy
Time of Update: 2023-02-02
Figure 3Conclusion of the studyTwo separate phase III studies have now shown the same degree of improvement in PFS in combination with Isa in addition to standard care (Pd or Kd) in patients with 1q21+, 1q21 gain, and 1q21 amplification.
-
The efficacy and safety of idelalisib in real-world relapsed and refractory follicular lymphoma have been demonstrated
Time of Update: 2023-02-02
Poke "Read Original" to see moreFour patients underwent hematopoietic stem cell transplantation (HSCT) after achieving complete remission with idelalisib, of which 3 patients received allogeneic-HSCT and 1 patient received autologous-HSCT.
-
"Rui" enjoys a new life, leads to the future | the first batch of PI3K delta inhibitors in China, Linplisset prescription, and the new journey of PI3K inhibitors sets sail
Time of Update: 2023-02-02
In November 2022, China's first new-generation highly selective PI3Kδ inhibitor, Linplisept (trade name: Intari), ® was officially approved by the National Medical Products Administration (NMPA) of Ch
-
2023 CASH| Professor Hu Yu: Bravely climb the peak of diagnosis and treatment of coagulation diseases and stride forward to the new development of hematology under the new situation
Time of Update: 2023-02-01
Moving forward and enlightening the future together! From January 6 to 8, 2023, the 3rd China Hematology Development Conference was grandly opened. THE CONFERENCE WAS HOSTED BY THE CHINESE ACADEMY OF
